Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 6169128, 11 pages
https://doi.org/10.1155/2017/6169128
Research Article

Baicalin Ameliorates Experimental Liver Cholestasis in Mice by Modulation of Oxidative Stress, Inflammation, and NRF2 Transcription Factor

1Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China
2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China
3Department of Urology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China
4Division of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China

Correspondence should be addressed to Shusen Zheng; nc.ude.ujz@gnehznesuhs

Received 25 March 2017; Revised 18 May 2017; Accepted 28 May 2017; Published 5 July 2017

Academic Editor: Aditya Sen

Copyright © 2017 Kezhen Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. S. Lim and W. R. Kim, “The global impact of hepatic fibrosis and end-stage liver disease,” Clinics in Liver Disease, vol. 12, pp. 733–746, 2008, vii. View at Publisher · View at Google Scholar · View at Scopus
  2. T. E. Starzl, A. J. Demetris, and D. Van Thiel, “Liver transplantation (1),” The New England Journal of Medicine, vol. 321, pp. 1014–1022, 1989. View at Publisher · View at Google Scholar
  3. M. A. Doyle, J. Singer, T. Lee, M. Muir, and C. Cooper, “Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial,” Trials, vol. 17, p. 331, 2016. View at Google Scholar
  4. Y. Koyama, J. Xu, X. Liu, and D. A. Brenner, “New developments on the treatment of liver fibrosis,” Digestive Diseases, vol. 34, pp. 589–596, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Shen, X. Feng, R. Su, H. Xie, L. Zhou, and S. Zheng, “Epigallocatechin 3-gallate ameliorates bile duct ligation induced liver injury in mice by modulation of mitochondrial oxidative stress and inflammation,” PloS One, vol. 10, article e0126278, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Mukhopadhyay, M. Rajesh, Z. Cao et al., “Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis,” Hepatology, vol. 59, pp. 1998–2009, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Kisseleva and D. A. Brenner, “Hepatic stellate cells and the reversal of fibrosis,” Journal of Gastroenterology and Hepatology, vol. 21, Supplement 3, pp. S84–S87, 2006. View at Google Scholar
  8. A. Canbay, P. Taimr, N. Torok, H. Higuchi, S. Friedman, and G. J. Gores, “Apoptotic body engulfment by a human stellate cell line is profibrogenic,” Laboratory Investigation, vol. 83, pp. 655–663, 2003. View at Publisher · View at Google Scholar
  9. A. Canbay, A. E. Feldstein, H. Higuchi et al., “Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression,” Hepatology, vol. 38, pp. 1188–1198, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. L. Harvey, R. Edrada-Ebel, and R. J. Quinn, “The re-emergence of natural products for drug discovery in the genomics era,” Nature Reviews Drug Discovery, vol. 14, pp. 111–129, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Wozniak, E. Lamer-Zarawska, and A. Matkowski, “Antimutagenic and antiradical properties of flavones from the roots of Scutellaria baicalensis georgi,” Die Nahrung, vol. 48, pp. 9–12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S. J. Kim, Y. J. Moon, and S. M. Lee, “Protective effects of baicalin against ischemia/reperfusion injury in rat liver,” Journal of Natural Products, vol. 73, pp. 2003–2008, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. L. Liu, L. K. Gong, H. Wang et al., “Baicalin protects mouse from concanavalin A-induced liver injury through inhibition of cytokine production and hepatocyte apoptosis,” Liver International, vol. 27, pp. 582–591, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Wang, Y. Zhang, R. Bai, M. Wang, and S. Du, “Baicalin attenuates alcoholic liver injury through modulation of hepatic oxidative stress, inflammation and sonic hedgehog pathway in rats,” Cellular Physiology and Biochemistry, vol. 39, pp. 1129–1140, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. L. Xi, H. X. Li, C. Chen et al., “Baicalin attenuates high fat diet-induced insulin resistance and ectopic fat storage in skeletal muscle, through modulating the protein kinase B/glycogen synthase kinase 3 beta pathway,” Chinese Journal of Natural Medicines, vol. 14, pp. 48–55, 2016. View at Google Scholar
  16. Y. Xi, M. Wu, H. Li et al., “Baicalin attenuates high fat diet-induced obesity and liver dysfunction: dose-response and potential role of CaMKKbeta/AMPK/ACC pathway,” Cellular Physiology and Biochemistry, vol. 35, pp. 2349–2359, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Qiao, H. Han, D. Hong, Z. Ren, Y. Chen, and C. Zhou, “Protective effects of baicalin on carbon tetrachloride induced liver injury by activating PPARgamma and inhibiting TGFbeta1,” Pharmaceutical Biology, vol. 49, pp. 38–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Shi, Q. Sheng, X. Xu, W. Huang, and Y. J. Kang, “Zinc supplementation suppresses the progression of bile duct ligation-induced liver fibrosis in mice,” Experimental Biology and Medicine, vol. 240, pp. 1197–1204, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Pan, J. Chen, K. Shen et al., “Mitochondrial modulation by epigallocatechin 3-gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice,” PloS One, vol. 10, article e0124775, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. D. E. Shieh, L. T. Liu, and C. C. Lin, “Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin,” Anticancer Research, vol. 20, pp. 2861–2865, 2000. View at Google Scholar
  21. B. Q. Li, T. Fu, W. H. Gong et al., “The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines,” Immunopharmacology, vol. 49, pp. 295–306, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Wang, J. Yang, X. Li, and J. Wang, “The metabolism of baicalin in rat and the biological activities of the metabolites,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 404529, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Y. Lai, S. L. Hsiu, S. Y. Tsai, Y. C. Hou, and P. D. Chao, “Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats,” The Journal of Pharmacy and Pharmacology, vol. 55, pp. 205–209, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Hinz, H. Franke, G. Machnik, A. Muller, and R. Dargel, “Histological and biochemical changes induced by total bile duct ligation in the rat,” Experimental and Toxicologic Pathology, vol. 49, pp. 281–288, 1997. View at Publisher · View at Google Scholar
  25. H. Malhi, M. E. Guicciardi, and G. J. Gores, “Hepatocyte death: a clear and present danger,” Physiological Reviews, vol. 90, pp. 1165–1194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Mukhopadhyay, J. Liu, D. Osei-Hyiaman et al., “Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma,” The Journal of Biological Chemistry, vol. 285, pp. 19002–19011, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M. D. Gorrell, “Liver fibrosis: the hepatocyte revisited,” Hepatology, vol. 46, pp. 1659–1661, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. S. W. Park, C. H. Lee, Y. S. Kim et al., “Protective effect of baicalin against carbon tetrachloride-induced acute hepatic injury in mice,” Journal of Pharmacological Sciences, vol. 106, pp. 136–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. L. L. Liu, L. K. Gong, H. Wang et al., “Baicalin inhibits macrophage activation by lipopolysaccharide and protects mice from endotoxin shock,” Biochemical Pharmacology, vol. 75, pp. 914–922, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Kolios, V. Valatas, and E. Kouroumalis, “Role of Kupffer cells in the pathogenesis of liver disease,” World Journal of Gastroenterology, vol. 12, pp. 7413–7420, 2006. View at Publisher · View at Google Scholar
  31. M. Orellana, R. Rodrigo, L. Thielemann, and V. Guajardo, “Bile duct ligation and oxidative stress in the rat: effects in liver and kidney,” Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, vol. 126, pp. 105–111, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. J. B. Hoek and J. G. Pastorino, “Ethanol, oxidative stress, and cytokine-induced liver cell injury,” Alcohol, vol. 27, pp. 63–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. C. C. Liao, Y. J. Day, H. C. Lee, J. T. Liou, A. H. Chou, and F. C. Liu, “Baicalin attenuates IL-17-mediated acetaminophen-induced liver injury in a mouse model,” PloS One, vol. 11, article e0166856, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. M. M. Tiao, T. K. Lin, P. W. Wang, J. B. Chen, and C. W. Liou, “The role of mitochondria in cholestatic liver injury,” Chang Gung Medical Journal, vol. 32, pp. 346–353, 2009. View at Google Scholar
  35. N. Alptekin, G. Mehmetcik, M. Uysal, and G. Aykac-toker, “Evidence for oxidative stress in the hepatic mitochondria of bile duct ligated rats,” Pharmacological Research, vol. 36, pp. 243–247, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. K. M. Holmstrom and T. Finkel, “Cellular mechanisms and physiological consequences of redox-dependent signalling,” Nature Reviews Molecular Cell Biology, vol. 15, pp. 411–421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Y. Waisundara, A. Hsu, B. K. Tan, and D. Huang, “Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats,” Diabetes/Metabolism Research and Reviews, vol. 25, pp. 671–677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. M. R. de Oliveira, S. F. Nabavi, S. Habtemariam, I. Erdogan Orhan, M. Daglia, and S. M. Nabavi, “The effects of baicalein and baicalin on mitochondrial function and dynamics: a review,” Pharmacological Research, vol. 100, pp. 296–308, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. W. H. Chang, C. H. Chen, and F. J. Lu, “Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines,” Planta Medica, vol. 68, pp. 128–132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. S. M. Shin, J. H. Yang, and S. H. Ki, “Role of the Nrf2-ARE pathway in liver diseases,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 763257, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. R. N. Jadeja, K. K. Upadhyay, R. V. Devkar, and S. Khurana, “Naturally occurring Nrf2 activators: potential in treatment of liver injury,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3453926, 13 pages, 2016. View at Publisher · View at Google Scholar
  42. H. Zhang, K. J. Davies, and H. J. Forman, “Oxidative stress response and Nrf2 signaling in aging,” Free Radical Biology & Medicine, vol. 88, pp. 314–336, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. O. Al-Sawaf, T. Clarner, A. Fragoulis et al., “Nrf2 in health and disease: current and future clinical implications,” Clinical Science, vol. 129, pp. 989–999, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. L. M. Aleksunes, A. L. Slitt, J. M. Maher et al., “Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis,” Cell Stress & Chaperones, vol. 11, pp. 356–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. F. J. Padillo, A. Cruz, C. Navarrete et al., “Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis,” Free Radical Research, vol. 38, pp. 697–704, 2004. View at Google Scholar
  46. C. Ara, H. Kirimlioglu, A. B. Karabulut et al., “Protective effect of resveratrol against oxidative stress in cholestasis,” The Journal of Surgical Research, vol. 127, pp. 112–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. J. E. Puche, Y. Saiman, and S. L. Friedman, “Hepatic stellate cells and liver fibrosis,” Comprehensive Physiology, vol. 3, pp. 1473–1492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. J. Arthur, D. A. Mann, and J. P. Iredale, “Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis,” Journal of Gastroenterology and Hepatology, vol. 13, pp. S33–S38, 1998. View at Google Scholar